C7A.098
BillableMalignant carcinoid tumors of other sites
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C7A.098 an HCC code?
Yes. C7A.098 maps to Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C7A.098
For C7A.098to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C7A.098 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C7A.098 is the ICD-10-CM diagnosis code for malignant carcinoid tumors of other sites. A rare cancer of hormone-producing cells found in various body locations other than the common sites (lungs, stomach, intestines, thymus). C7A.098 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Under the CMS-HCC V28 risk adjustment model, C7A.098 maps to Lymphoma and Other Cancers (HCC 21) with a community, non-dual, aged base RAF weight of 0.671. Under the older CMS-HCC V24 model, C7A.098 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This is a catch-all code; document the specific anatomical site in the medical record for clarity and future reference. Because C7A.098 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7A.098 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This is a catch-all code; document the specific anatomical site in the medical record for clarity and future reference
- •Verify that the site does not fit into more specific carcinoid codes (C7A.0-C7A.09) before assigning this code
Clinical Significance
Malignant carcinoid tumors of other sites is a residual category for primary neuroendocrine carcinoid tumors arising in anatomic locations not specified by other C7A codes, such as the ovary, testis, hepatobiliary system, or other uncommon sites. These rare presentations require meticulous pathologic documentation to confirm the primary site and distinguish from metastatic carcinoid disease. The unusual location often delays diagnosis and may necessitate specialized multidisciplinary oncologic management.
Documentation Requirements
- ✓Pathology confirming neuroendocrine/carcinoid histology with immunohistochemistry
- ✓Specific anatomic site clearly documented as the primary origin
- ✓Evidence that the tumor does not fit into existing site-specific C7A codes (C7A.00-C7A.096)
- ✓Workup confirming this is a primary tumor at the site, not metastatic disease
- ✓Tumor grade, stage, and Ki-67 index
- ✓Treatment plan and surveillance protocol
Commonly Confused Codes
- •C7A.00-C7A.096 — Site-specific carcinoid codes: Always check if a more specific code exists before using C7A.098
- •C7B.09 — Secondary carcinoid tumors of other sites: Use C7B codes for metastatic carcinoid disease, not C7A.098
- •C7A.8 — Other malignant neuroendocrine tumors: Use C7A.8 for non-carcinoid neuroendocrine tumors; C7A.098 is specifically carcinoid type